Patents by Inventor Nick SCORAH

Nick SCORAH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP receptor agonist peptide compounds and uses thereof
    Patent number: 12122815
    Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 328-893.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: October 22, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Hiroshi Imoto, Mari Adachi, Yoko Kanematsu, Taiji Asami, Ayumu Niida, Naoki Nishizawa, Derek Cecil Cole, Mack Flinspach, Nick Scorah, Abhijit Suresh Bhat
  • GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF
    Publication number: 20220135638
    Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.
    Type: Application
    Filed: September 24, 2019
    Publication date: May 5, 2022
    Inventors: Hiroshi IMOTO, Mari ADACHI, Yoko KANEMATSU, Taiji ASAMI, Ayumu NIIDA, Naoki NISHIZAWA, Derek Cecil COLE, Mack FLINSPACH, Nick SCORAH, Abhijit Suresh BHAT
  • GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF
    Publication number: 20220016215
    Abstract: The present disclosure provides GIF receptor agonist peptide compounds having an activating action on GIF receptors and use of the GIF receptor agonist peptide as a medicament for the treatment and/or prevention of emesis. Specifically, a GIF receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are N provided. Formula (I) P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-P2, wherein each symbol is as defined herein, with the proviso that the GIF receptor agonist peptide is not native human GIF having an amino acid sequence as set forth in SEQ ID NO: 1.
    Type: Application
    Filed: September 24, 2019
    Publication date: January 20, 2022
    Inventors: Shiro TAKEKAWA, Tomoko MORIMOTO, Minoru MARUYAMA, Hiroaki NAGAI, Akira TANAKA, Hisanori MATSUI, Atsuko OBINATA, Derek Cecil COLE, Mack FLINSPACH, Nick SCORAH, Abhijit Suresh BHAT